Chandrabose Karthikeyan1, Crystal Lee2, Joshua Moore2, Roopali Mittal3, Esther A Suswam4, Kodye L Abbott5, Satyanarayana R Pondugula5, Upender Manne4, Narayanan K Narayanan6, Piyush Trivedi7, Amit K Tiwari8. 1. School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal 462033, MP, India. 2. Department of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, CVMNAH, Tuskegee University, Tuskegee, AL 36088, USA. 3. Pediatric Gastroenterology and Nutrition, Oklahoma State University, Oklahoma City, OK 73104, USA. 4. Department of Pathology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 5. Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA. 6. New York University School of Medicine, New York, NY, USA. 7. School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal 462033, MP, India. Electronic address: piyush.trivedi@rgtu.net. 8. Department of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, CVMNAH, Tuskegee University, Tuskegee, AL 36088, USA. Electronic address: atiwari@mytu.tuskegee.edu.
Abstract
Naturally occurring condensed quinolines have anticancer properties. In efforts to find active analogues, we designed and synthesized eight polycyclic heterocycles with a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline framework (IND series). The compounds were evaluated for activity against colon (HCT-116 and S1-MI-80), prostate (PC3 and DU-145), breast (MCF-7 and MDAMB-231), ovarian (ov2008 and A2780), and hepatocellular (HepG2) cancer cells and against non-cancerous Madin Darby canine kidney (MDCK), mouse embryonic fibroblast (NIH/3T3), and human embryonic kidney cells (HEK293). IND-2, a 4-chloro-2-methyl pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline, exhibited more than ten-fold selectivity and potent cytotoxic activity against colon cancer cells relative to the other cancer and non-cancer cells. With five additional colon cancer cell lines (HT-29, HCT-15, LS-180, LS-174, and LoVo), IND-2 had similar cytotoxicity and selectivity, and sub-micromolar concentrations caused changes in the morphology of HCT-116 and HCT-15 cells. IND-2 did not activate the transactivating function of the pregnane X receptor (PXR), indicating that it does not induce PXR-regulated ABCB1 or ABCG2 transporters. Indeed, IND-2 was not a substrate of ABCB1 or ABCG2, and it induced cytotoxicity in HEK293 cells overexpressing ABCB1 or ABCG2 to the same extent as in normal HEK293 cells. IND-2 was cytotoxic to resistant colon carcinoma S1-MI-80 cells, approximately three- and five-fold more than SN-38 and topotecan, respectively. In HCT-116 colon cancer cells, IND-2 produced concentration-dependent changes in mitochondrial membrane potential, leading to apoptosis, and sub-micromolar concentrations caused chromosomal DNA fragmentation. These findings suggest that, by increasing apoptosis, IND-2 has potential therapeutic efficacy for colorectal cancer.
Naturally occurring condensed n class="Chemical">quinolines have anticancer properties. In efforts to find active analogues, we designed and synthesized eight polycyclic heterocycles with a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline framework (IND series). The compounds were evaluated for activity against colon (HCT-116 and S1-MI-80), prostate (PC3 and DU-145), breast (MCF-7 and MDAMB-231), ovarian (ov2008 and A2780), and hepatocellular (HepG2) cancer cells and against non-cancerous Madin Darby canine kidney (MDCK), mouse embryonic fibroblast (NIH/3T3), and humanembryonic kidney cells (HEK293). IND-2, a4-chloro-2-methyl pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline, exhibited more than ten-fold selectivity and potent cytotoxic activity against colon cancer cells relative to the other cancer and non-cancer cells. With five additional colon cancer cell lines (HT-29, HCT-15, LS-180, LS-174, and LoVo), IND-2 had similar cytotoxicity and selectivity, and sub-micromolar concentrations caused changes in the morphology of HCT-116 and HCT-15 cells. IND-2 did not activate the transactivating function of the pregnane X receptor (PXR), indicating that it does not induce PXR-regulated ABCB1 or ABCG2 transporters. Indeed, IND-2 was not a substrate of ABCB1 or ABCG2, and it induced cytotoxicity in HEK293 cells overexpressing ABCB1 or ABCG2 to the same extent as in normal HEK293 cells. IND-2 was cytotoxic to resistant colon carcinoma S1-MI-80 cells, approximately three- and five-fold more than SN-38 and topotecan, respectively. In HCT-116colon cancer cells, IND-2 produced concentration-dependent changes in mitochondrial membrane potential, leading to apoptosis, and sub-micromolar concentrations caused chromosomal DNA fragmentation. These findings suggest that, by increasing apoptosis, IND-2 has potential therapeutic efficacy for colorectal cancer.
Authors: L Dassonneville; A Lansiaux; A Wattelet; N Wattez; C Mahieu; S Van Miert; L Pieters; C Bailly Journal: Eur J Pharmacol Date: 2000-12-01 Impact factor: 4.432
Authors: R W Robey; W Y Medina-Pérez; K Nishiyama; T Lahusen; K Miyake; T Litman; A M Senderowicz; D D Ross; S E Bates Journal: Clin Cancer Res Date: 2001-01 Impact factor: 12.531
Authors: Haneen Amawi; Noor A Hussein; Charles R Ashby; Rawan Alnafisah; Leticia M Sanglard; Elangovan Manivannan; Chandrabose Karthikeyan; Piyush Trivedi; Kathryn M Eisenmann; Robert W Robey; Amit K Tiwari Journal: Front Pharmacol Date: 2018-05-23 Impact factor: 5.810
Authors: Mark Kelada; John M D Walsh; Robert W Devine; Patrick McArdle; John C Stephens Journal: Beilstein J Org Chem Date: 2018-05-28 Impact factor: 2.883
Authors: Chandrabose Karthikeyan; Haneen Amawi; Charles R Ashby; Vishwa M Khare; Veronica Jones; N S Hari Narayana Moorthy; Piyush Trivedi; Amit K Tiwari Journal: Heliyon Date: 2019-05-14